Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study

PURPOSE: The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase inhibitor, administered as third-line or further treatment prolonged progression-free survival (PFS) and overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC). This retrospective s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Kun, Ma, Xiya, Gao, Hongjun, Wang, Hong, Qin, Haifeng, Yang, Shaoxing, Liu, Xiaoqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231784/
https://www.ncbi.nlm.nih.gov/pubmed/32494205
http://dx.doi.org/10.2147/CMAR.S246000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231784/
https://www.ncbi.nlm.nih.gov/pubmed/32494205
http://dx.doi.org/10.2147/CMAR.S246000

Ejemplares similares